May SAS-B approvals hit 2026 high as Victoria extends prescribing lead by Adam Sheldon June 3, 2026June 4, 2026 Approvals through the Special Access Scheme reached a 2026 high in May, with Victoria accounting for […]
April SAS-B figures: pastilles hit nearly one-third of approvals by Adam Sheldon May 7, 2026May 7, 2026
Lancet clinical review paper: why absence of evidence is not evidence of absence by Andrew Proudfoot March 18, 2026March 18, 2026
Prices continue to tumble as market sees rapid rise in product numbers by Adam Sheldon March 3, 2026March 5, 2026
Pastilles surge again as SAS-B data shows strong start to 2026 by Steve Jones February 2, 2026February 3, 2026
SAS-B deep dive: approvals climb 26% in 2025 as flower overtakes oil and pastilles surge by Adam Sheldon January 13, 2026January 14, 2026
AP approvals fall as medicinal cannabis sales plateau, Penington report finds by Adam Sheldon December 3, 2025December 4, 2025
Pastilles climb past oil to become second largest SAS-B dosage form by Steve Jones December 2, 2025December 4, 2025
October SAS-B approvals hit second highest number on record by Steve Jones November 3, 2025November 4, 2025
